Logo image of ADN1.DE

ADESSO SE (ADN1.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:ADN1 - DE000A0Z23Q5 - Common Stock

82.9 EUR
-1.6 (-1.89%)
Last: 1/21/2026, 5:23:56 PM
Fundamental Rating

5

ADN1 gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 76 industry peers in the IT Services industry. ADN1 has only an average score on both its financial health and profitability. ADN1 is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • ADN1 had positive earnings in the past year.
  • ADN1 had a positive operating cash flow in the past year.
  • ADN1 had positive earnings in each of the past 5 years.
  • ADN1 had a positive operating cash flow in each of the past 5 years.
ADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFADN1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 2.45%, ADN1 is doing worse than 64.47% of the companies in the same industry.
  • ADN1 has a Return On Equity (10.90%) which is in line with its industry peers.
  • The Return On Invested Capital of ADN1 (5.23%) is worse than 65.79% of its industry peers.
  • ADN1 had an Average Return On Invested Capital over the past 3 years of 3.16%. This is significantly below the industry average of 25.98%.
  • The 3 year average ROIC (3.16%) for ADN1 is below the current ROIC(5.23%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.45%
ROE 10.9%
ROIC 5.23%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ADN1.DE Yearly ROA, ROE, ROICADN1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

  • The Profit Margin of ADN1 (0.99%) is worse than 67.11% of its industry peers.
  • ADN1's Profit Margin has declined in the last couple of years.
  • ADN1 has a worse Operating Margin (2.96%) than 68.42% of its industry peers.
  • In the last couple of years the Operating Margin of ADN1 has declined.
  • ADN1's Gross Margin of 85.30% is fine compared to the rest of the industry. ADN1 outperforms 76.32% of its industry peers.
  • ADN1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.96%
PM (TTM) 0.99%
GM 85.3%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
ADN1.DE Yearly Profit, Operating, Gross MarginsADN1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ADN1 is destroying value.
  • ADN1 has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ADN1 has been increased compared to 5 years ago.
  • The debt/assets ratio for ADN1 has been reduced compared to a year ago.
ADN1.DE Yearly Shares OutstandingADN1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ADN1.DE Yearly Total Debt VS Total AssetsADN1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • ADN1 has an Altman-Z score of 3.60. This indicates that ADN1 is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.60, ADN1 is doing good in the industry, outperforming 75.00% of the companies in the same industry.
  • The Debt to FCF ratio of ADN1 is 7.88, which is on the high side as it means it would take ADN1, 7.88 years of fcf income to pay off all of its debts.
  • ADN1's Debt to FCF ratio of 7.88 is on the low side compared to the rest of the industry. ADN1 is outperformed by 69.74% of its industry peers.
  • A Debt/Equity ratio of 1.60 is on the high side and indicates that ADN1 has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.60, ADN1 is doing worse than 78.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF 7.88
Altman-Z 3.6
ROIC/WACC0.51
WACC10.18%
ADN1.DE Yearly LT Debt VS Equity VS FCFADN1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.3 Liquidity

  • ADN1 has a Current Ratio of 1.30. This is a normal value and indicates that ADN1 is financially healthy and should not expect problems in meeting its short term obligations.
  • ADN1's Current ratio of 1.30 is in line compared to the rest of the industry. ADN1 outperforms 51.32% of its industry peers.
  • A Quick Ratio of 1.30 indicates that ADN1 should not have too much problems paying its short term obligations.
  • The Quick ratio of ADN1 (1.30) is better than 61.84% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 1.3
ADN1.DE Yearly Current Assets VS Current LiabilitesADN1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 200.98% over the past year.
  • The earnings per share for ADN1 have been decreasing by -15.02% on average. This is quite bad
  • ADN1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.60%.
  • The Revenue has been growing by 23.60% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)200.98%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%9.8%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%13.44%

3.2 Future

  • Based on estimates for the next years, ADN1 will show a very strong growth in Earnings Per Share. The EPS will grow by 39.34% on average per year.
  • The Revenue is expected to grow by 10.28% on average over the next years. This is quite good.
EPS Next Y83.56%
EPS Next 2Y76.08%
EPS Next 3Y63.28%
EPS Next 5Y39.34%
Revenue Next Year10.53%
Revenue Next 2Y10.3%
Revenue Next 3Y10.23%
Revenue Next 5Y10.28%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADN1.DE Yearly Revenue VS EstimatesADN1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
ADN1.DE Yearly EPS VS EstimatesADN1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5 10

5

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 25.99 indicates a quite expensive valuation of ADN1.
  • The rest of the industry has a similar Price/Earnings ratio as ADN1.
  • ADN1's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.94.
  • Based on the Price/Forward Earnings ratio of 14.66, the valuation of ADN1 can be described as correct.
  • 61.84% of the companies in the same industry are more expensive than ADN1, based on the Price/Forward Earnings ratio.
  • ADN1's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.94.
Industry RankSector Rank
PE 25.99
Fwd PE 14.66
ADN1.DE Price Earnings VS Forward Price EarningsADN1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ADN1 is valued a bit cheaper than the industry average as 69.74% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, ADN1 is valued a bit cheaper than 65.79% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.58
EV/EBITDA 6.41
ADN1.DE Per share dataADN1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 100 200 300

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ADN1's earnings are expected to grow with 63.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y76.08%
EPS Next 3Y63.28%

4

5. Dividend

5.1 Amount

  • ADN1 has a yearly dividend return of 0.83%, which is pretty low.
  • Compared to an average industry Dividend Yield of 2.10, ADN1 has a dividend in line with its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.83, ADN1's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.83%

5.2 History

  • The dividend of ADN1 is nicely growing with an annual growth rate of 15.65%!
Dividend Growth(5Y)15.65%
Div Incr Years5
Div Non Decr Years6
ADN1.DE Yearly Dividends per shareADN1.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

  • ADN1 pays out 31.75% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of ADN1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP31.75%
EPS Next 2Y76.08%
EPS Next 3Y63.28%
ADN1.DE Yearly Income VS Free CF VS DividendADN1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ADN1.DE Dividend Payout.ADN1.DE Dividend Payout, showing the Payout Ratio.ADN1.DE Dividend Payout.PayoutRetained Earnings

ADESSO SE

FRA:ADN1 (1/21/2026, 5:23:56 PM)

82.9

-1.6 (-1.89%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)11-12
Earnings (Next)03-31
Inst Owners20.34%
Inst Owner ChangeN/A
Ins Owners50.28%
Ins Owner ChangeN/A
Market Cap541.34M
Revenue(TTM)2.10B
Net Income(TTM)20.84M
Analysts83.33
Price Target130.39 (57.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.83%
Yearly Dividend0.94
Dividend Growth(5Y)15.65%
DP31.75%
Div Incr Years5
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.97%
PT rev (3m)2.03%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-10.38%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.07%
Valuation
Industry RankSector Rank
PE 25.99
Fwd PE 14.66
P/S 0.26
P/FCF 11.58
P/OCF 6.97
P/B 2.83
P/tB 10.69
EV/EBITDA 6.41
EPS(TTM)3.19
EY3.85%
EPS(NY)5.65
Fwd EY6.82%
FCF(TTM)7.16
FCFY8.64%
OCF(TTM)11.9
OCFY14.35%
SpS322.11
BVpS29.27
TBVpS7.75
PEG (NY)0.31
PEG (5Y)N/A
Graham Number45.84
Profitability
Industry RankSector Rank
ROA 2.45%
ROE 10.9%
ROCE 11.91%
ROIC 5.23%
ROICexc 5.78%
ROICexgc 8.22%
OM 2.96%
PM (TTM) 0.99%
GM 85.3%
FCFM 2.22%
ROA(3y)1.93%
ROA(5y)3.99%
ROE(3y)6.49%
ROE(5y)13.12%
ROIC(3y)3.16%
ROIC(5y)4.51%
ROICexc(3y)4.06%
ROICexc(5y)6.01%
ROICexgc(3y)6.65%
ROICexgc(5y)10.11%
ROCE(3y)7.2%
ROCE(5y)10.26%
ROICexgc growth 3Y-20.34%
ROICexgc growth 5Y-12.01%
ROICexc growth 3Y-21.84%
ROICexc growth 5Y-11.01%
OM growth 3Y-30%
OM growth 5Y-15.03%
PM growth 3Y-55.28%
PM growth 5Y-30.54%
GM growth 3Y-0.02%
GM growth 5Y-0.7%
F-Score7
Asset Turnover2.47
Health
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF 7.88
Debt/EBITDA 2.26
Cap/Depr 42.37%
Cap/Sales 1.47%
Interest Coverage 5.03
Cash Conversion 57.42%
Profit Quality 224.33%
Current Ratio 1.3
Quick Ratio 1.3
Altman-Z 3.6
F-Score7
WACC10.18%
ROIC/WACC0.51
Cap/Depr(3y)52.06%
Cap/Depr(5y)49.68%
Cap/Sales(3y)2.64%
Cap/Sales(5y)2.54%
Profit Quality(3y)790.41%
Profit Quality(5y)538.39%
High Growth Momentum
Growth
EPS 1Y (TTM)200.98%
EPS 3Y-45.14%
EPS 5Y-15.02%
EPS Q2Q%9.8%
EPS Next Y83.56%
EPS Next 2Y76.08%
EPS Next 3Y63.28%
EPS Next 5Y39.34%
Revenue 1Y (TTM)12.6%
Revenue growth 3Y24.12%
Revenue growth 5Y23.6%
Sales Q2Q%13.44%
Revenue Next Year10.53%
Revenue Next 2Y10.3%
Revenue Next 3Y10.23%
Revenue Next 5Y10.28%
EBIT growth 1Y38.36%
EBIT growth 3Y-13.12%
EBIT growth 5Y5.01%
EBIT Next Year304.77%
EBIT Next 3Y78.82%
EBIT Next 5Y44.13%
FCF growth 1Y300.77%
FCF growth 3Y40.19%
FCF growth 5Y49.54%
OCF growth 1Y1010.67%
OCF growth 3Y32.14%
OCF growth 5Y37.69%

ADESSO SE / ADN1.DE FAQ

What is the ChartMill fundamental rating of ADESSO SE (ADN1.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to ADN1.DE.


Can you provide the valuation status for ADESSO SE?

ChartMill assigns a valuation rating of 5 / 10 to ADESSO SE (ADN1.DE). This can be considered as Fairly Valued.


What is the profitability of ADN1 stock?

ADESSO SE (ADN1.DE) has a profitability rating of 4 / 10.


What are the PE and PB ratios of ADESSO SE (ADN1.DE) stock?

The Price/Earnings (PE) ratio for ADESSO SE (ADN1.DE) is 25.99 and the Price/Book (PB) ratio is 2.83.


Can you provide the expected EPS growth for ADN1 stock?

The Earnings per Share (EPS) of ADESSO SE (ADN1.DE) is expected to grow by 83.56% in the next year.